Amgen Inc. (AMGN)
| Market Cap | 185.54B |
| Revenue (ttm) | 35.97B |
| Net Income (ttm) | 7.01B |
| Shares Out | 538.48M |
| EPS (ttm) | 12.93 |
| PE Ratio | 26.64 |
| Forward PE | 16.36 |
| Dividend | $9.52 (2.76%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 2,328,615 |
| Open | 341.53 |
| Previous Close | 341.11 |
| Day's Range | 340.00 - 345.03 |
| 52-Week Range | 253.30 - 345.84 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 313.31 (-9.07%) |
| Earnings Date | Nov 4, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $313.31, which is a decrease of -9.07% from the latest price.
News
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m.
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference at 10:00 a.m.
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With ...
Why Amgen Stock Edged Past the Market on Thursday
It appears that some investors took a pair of new and bullish pundit takes to heart. One of the pair was a famous stock picker who appears regularly on TV.
Trade Tracker: Bill Baruch buys more Amgen
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector.
Cramer's Stop Trading: Amgen
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
2 Supercharged Dividend Stocks to Buy Now
Amgen is performing well despite some headwinds, and its pipeline is progressing. Gilead Sciences' strong core franchise and diversification efforts should work wonders.
There Are Non-AI Stocks Worth Buying. Start With This List.
Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.
Why Amgen Stock Was a Nearly 5% Winner Today
An analyst bumped his price target higher on the shares. He didn't change his recommendation, however.
Three Healthcare Buys That Wall Street Loves
New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.
Amgen CEO talks trial results of cardiac drug Repatha
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
CEO of drugmaker Amgen talks new results from cholesterol drug trial
Amgen CEO Bob Bradway told CNBC's Jim Cramer that a new trial showed his company's drug can reduce the risk of heart attack. "This trial answered questions that have been on the mind of investigators ...
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8, ...
Amgen cholesterol drug cuts risk of first cardiac event by 25%
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a lar...
Amgen: Buy This Cheap Biotech Leader
Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised f...
Stock Of The Day: Will Amgen Reverse Again?
Amgen Inc. (NASDAQ:AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings.
Why Amgen Stock Was Crushing It on Wednesday
The biotech and pharmaceutical mainstay posted its third-quarter results. It was a beat-and-raise quarter that featured double-digit growth on the top line.
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D
Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth. AMGN delivered strong Q3 results, with double-digit revenue and volume gro...
Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript
Amgen Inc. ( AMGN) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Casey Capparelli Robert Bradway - Chairman, CEO & President Peter Griffith - Executive VP & CFO Murdo Gordon...
Amgen Raises Full-Year Outlook After Third-Quarter Profit, Sales Jump
The biotechnology company reported a profit of $3.22 billion thanks to a 12% rise in product sales.
Amgen profit beats estimates, weight-loss data due by year-end
Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations as product sales rose 12%, offsetting higher operating expenses related to experimental weight-loss drug MariTi...
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.
